A drug that helps severed spinal nerves regrow is about to be tested in humans for the first time. This matters because spinal cord injuries currently have no effective treatments. When the nerve roots connecting a limb to the spinal cord are torn—a condition called brachial plexus avulsion—patients are left with a permanently paralysed and numb arm. The drug, KCL-286, works by activating a receptor that dampens the scar tissue blocking nerve regrowth and switches on the neurons’ own repair programs. In rats, it restored sensory function. If the phase 1 trial shows the drug is safe and reaches the right levels in the body, the team plans a small phase 2a study in men with brachial plexus avulsion. Success could lead to the first treatment for this specific injury. The drug might also work for other central nervous system damage, including stroke and traumatic brain injury, potentially changing how these common, devastating conditions are managed.
View original technical description
There are no effective treatments for spinal cord injuries (SCIs). We have developed a novel orally available retinoic acid receptor beta (RARb) agonist, KCL-286, that induces axonal regeneration in an adult rat model of brachial plexus avulsion (BPA). In BPAs the motor and sensory roots are severed from the spinal cord and the latter never regenerate, leaving these patients with a permanently impaired limb. KCL- 286 modulates inhibitory components of the injury induced glial scar and intrinsic neuronal programs, promoting axonal regeneration in the central nervous system (CNS) and permitting sensory recovery. The proposed project is to carry out a first in man (FIM) study, to investigate the pharmacokinetics and tolerability of single and multiple oral doses of KCL-286 with the aim to define a dose range that we predict will be efficacious based on evidence from the animal model. Target engagement will also be assessed as a surrogate measurement of KCL-286 activity, using a biomarker identified in the rat that is regulated by RARb. Additionally, a putative regeneration marker has also been identified and further studies will be carried out to validate its use as a prognostic biomarker. If successful, the phase 1 trial is intended to be followed by a small exploratory phase 2a study in male patients who experience BPA, to assess efficacy. Funds for this proof of concept (POC) study are not sought in this current application but a team of surgeons specialised in this injury has been set up in preparation for the possible forthcoming trial. BPA qualifies for orphan drug designation (ODD) for which we intend to apply. Additionally, KCL-286 will potentially have a considerably wider applicability to other CNS injuries, such as stroke, contusions and traumatic brain injuries (TBI), which could lead to valuable healthcare benefits.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know